{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:14:55Z","timestamp":1762254895816,"version":"3.37.3"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00228-024-03713-6","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T09:06:55Z","timestamp":1718701615000},"page":"1373-1385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-8135","authenticated-orcid":false,"given":"Francisco Cezar Aquino","family":"de Moraes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8317-1857","authenticated-orcid":false,"given":"Vitor Kendi Tsuchiya","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4723-4563","authenticated-orcid":false,"given":"Caroline R. M.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5478-4405","authenticated-orcid":false,"given":"Estella Aparecida","family":"de Laia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9103-9119","authenticated-orcid":false,"given":"Carlos","family":"Stecca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7748-8399","authenticated-orcid":false,"given":"Maria Cristina Figueroa","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4872-234X","authenticated-orcid":false,"given":"Rommel Mario Rodr\u00edguez","family":"Burbano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"3713_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M et al (2022) Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 66:15\u201323","journal-title":"Breast"},{"key":"3713_CR2","unstructured":"Reeves RA, Kaufman T (2024) Mammography. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing [cited 2024 Jan 23]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559310\/"},{"key":"3713_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17\u201348","journal-title":"CA Cancer J Clin"},{"key":"3713_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/genes15020145","volume":"15","author":"GG da Costa Nunes","year":"2024","unstructured":"da Costa Nunes GG, de Freitas LM, Monte N, Gellen LPA, Santos AP, de Moraes FCA et al (2024) Genomic variants and worldwide epidemiology of breast cancer: a genome-wide association studies correlation analysis. Genes (Basel) 15:145","journal-title":"Genes (Basel)"},{"key":"3713_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3390\/jpm14050464","volume":"14","author":"FCA de Moraes","year":"2024","unstructured":"de Moraes FCA, de Oliveira Almeida G, Alves VFC, Priantti JN, da Gomes GC, Carnevalli SVB et al (2024) Cyclin-dependent kinase 4\/6 inhibitors plus endocrine therapy versus endocrine therapy alone for HR-positive, HER-2-negative early breast cancer: meta-analysis of phase III randomized clinical trials. J Pers Med. 14:464","journal-title":"J Pers Med."},{"key":"3713_CR6","unstructured":"Health and Economic Benefits of Breast Cancer Interventions | Power of Prevention [Internet]. [cited 2024 Jan 23]. Available from: https:\/\/www.cdc.gov\/chronicdisease\/programs-impact\/pop\/breast-cancer.htm"},{"key":"3713_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature10912","volume":"485","author":"AC Hsieh","year":"2012","unstructured":"Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A et al (2012) The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485:55\u201361","journal-title":"Nature"},{"key":"3713_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/1758834014530023","volume":"6","author":"E Paplomata","year":"2014","unstructured":"Paplomata E, O\u2019Regan R (2014) The PI3K\/AKT\/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol 6:154\u2013166","journal-title":"Ther Adv Med Oncol"},{"key":"3713_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ctrv.2012.11.002","volume":"39","author":"AM Gonzalez-Angulo","year":"2013","unstructured":"Gonzalez-Angulo AM, Blumenschein GR (2013) Defining biomarkers to predict sensitivity to PI3K\/Akt\/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 39:313\u2013320","journal-title":"Cancer Treat Rev"},{"key":"3713_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","volume":"59","author":"AS Alzahrani","year":"2019","unstructured":"Alzahrani AS (2019) PI3K\/Akt\/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol 59:125\u2013132","journal-title":"Semin Cancer Biol"},{"key":"3713_CR11","doi-asserted-by":"publisher","first-page":"10304","DOI":"10.1021\/bi0202530","volume":"41","author":"H Reuveni","year":"2002","unstructured":"Reuveni H, Livnah N, Geiger T, Klein S, Ohne O, Cohen I et al (2002) Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry 41:10304\u201310314","journal-title":"Biochemistry"},{"key":"3713_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-021-01137-8","volume":"14","author":"H Hua","year":"2021","unstructured":"Hua H, Zhang H, Chen J, Wang J, Liu J, Jiang Y (2021) Targeting Akt in cancer for precision therapy. J Hematol Oncol 14:128","journal-title":"J Hematol Oncol"},{"key":"3713_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.662232","volume":"12","author":"F Martorana","year":"2021","unstructured":"Martorana F, Motta G, Pavone G, Motta L, Stella S, Vitale SR et al (2021) AKT inhibitors: new weapons in the fight against breast cancer? Front Pharmacol 12:662232","journal-title":"Front Pharmacol"},{"key":"3713_CR14","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1021\/jm301762v","volume":"56","author":"M Addie","year":"2013","unstructured":"Addie M, Ballard P, Buttar D, Crafter C, Currie G, Davies BR et al (2013) Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J Med Chem 56:2059\u20132073","journal-title":"J Med Chem"},{"key":"3713_CR15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1517\/13543776.2011.587959","volume":"21","author":"ME Mattmann","year":"2011","unstructured":"Mattmann ME, Stoops SL, Lindsley CW (2011) Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape. Expert Opin Ther Pat 21:1309\u20131338","journal-title":"Expert Opin Ther Pat"},{"key":"3713_CR16","doi-asserted-by":"publisher","first-page":"OT-35\u201301","DOI":"10.1158\/1538-7445.SABCS20-OT-35-01","volume":"81","author":"M Oliveira","year":"2021","unstructured":"Oliveira M, Villagrasa P, Ciruelos E, Gavil\u00e1 J, Cortegoso A, Henao F et al (2021) Abstract OT-35\u201301: Solti-1507 A phase ib study of ipatasertib and anti-her2 therapy in her2-positive advanced breast cancer with pik3ca mutation (ipather). Cancer Research. 81:OT-35-01","journal-title":"Cancer Research."},{"key":"3713_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","volume":"142","author":"J Polivka","year":"2014","unstructured":"Polivka J, Janku F (2014) Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway. Pharmacol Ther 142:164\u2013175","journal-title":"Pharmacol Ther"},{"key":"3713_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.semcancer.2019.06.002","volume":"59","author":"S Revathidevi","year":"2019","unstructured":"Revathidevi S, Munirajan AK (2019) Akt in cancer: mediator and more. Semin Cancer Biol 59:80\u201391","journal-title":"Semin Cancer Biol"},{"key":"3713_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.990874","author":"M Guerau-de-Arellano","year":"2022","unstructured":"Guerau-de-Arellano M, Piedra-Quintero ZL, Tsichlis PN (2022) Akt isoforms in the immune system. Front Immunol\u00a0[Internet]. https:\/\/doi.org\/10.3389\/fimmu.2022.990874","journal-title":"Front Immunol\u00a0[Internet]"},{"key":"3713_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1042\/BJ20081056","volume":"415","author":"V Duronio","year":"2008","unstructured":"Duronio V (2008) The life of a cell: apoptosis regulation by the PI3K\/PKB pathway. Biochem J 415:333\u2013344","journal-title":"Biochem J"},{"key":"3713_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","volume":"15","author":"F Janku","year":"2018","unstructured":"Janku F, Yap TA, Meric-Bernstam F (2018) Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol 15:273\u2013291","journal-title":"Nat Rev Clin Oncol"},{"key":"3713_CR22","first-page":"1517","volume":"14","author":"N Coleman","year":"2021","unstructured":"Coleman N, Moyers JT, Harbery A, Vivanco I, Yap TA (2021) Clinical development of AKT inhibitors and associated predictive biomarkers to guide patient treatment in cancer medicine. Pharmgenomics Pers Med 14:1517\u20131535","journal-title":"Pharmgenomics Pers Med"},{"key":"3713_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0065-230X(05)94002-5","volume":"94","author":"A Bellacosa","year":"2005","unstructured":"Bellacosa A, Kumar CC, Di Cristofano A, Testa JR (2005) Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94:29\u201386","journal-title":"Adv Cancer Res"},{"key":"3713_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ctim.2019.01.027","volume":"43","author":"Z Wang","year":"2019","unstructured":"Wang Z, Yin G, Jia R (2019) Impacts of self-care education on adverse events and mental health related quality of life in breast cancer patients under chemotherapy. Complement Ther Med 43:165\u2013169","journal-title":"Complement Ther Med"},{"key":"3713_CR25","doi-asserted-by":"publisher","first-page":"724","DOI":"10.5604\/12321966.1185784","volume":"22","author":"M Kami\u0144ska","year":"2015","unstructured":"Kami\u0144ska M, Ciszewski T, Kukie\u0142ka-Budny B, Kubiatowski T, Baczewska B, Makara-Studzi\u0144ska M et al (2015) Life quality of women with breast cancer after mastectomy or breast conserving therapy treated with adjuvant chemotherapy. Ann Agric Environ Med 22:724\u2013730","journal-title":"Ann Agric Environ Med"},{"key":"3713_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1515\/pjs-2016-0062","volume":"88","author":"B Szutowicz-Wydra","year":"2016","unstructured":"Szutowicz-Wydra B, Wydra J, Kruszewski WJ, Ciesielski M, Szajewski M, Walczak J et al (2016) Same quality of life for Polish breast cancer patients treated with mastectomy and breast reconstruction or breast-conserving therapy. Pol Przegl Chir 88:264\u2013269","journal-title":"Pol Przegl Chir"},{"key":"3713_CR27","doi-asserted-by":"publisher","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112:90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009","DOI":"10.1016\/j.ad.2019.05.009"},{"key":"3713_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13058-019-1154-8","volume":"21","author":"Y Xing","year":"2019","unstructured":"Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A et al (2019) Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and\/or PTEN loss\/PTEN mutation. Breast Cancer Res 21:78","journal-title":"Breast Cancer Res"},{"key":"3713_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"3713_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u201347","journal-title":"Eur J Cancer"},{"key":"3713_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"3713_CR32","doi-asserted-by":"publisher","unstructured":"Higgins JP, Savovi\u0107 J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. John Wiley & Sons, Ltd; 2019 [cited 2024 Jan 23]. p. 205\u201328. https:\/\/doi.org\/10.1002\/9781119536604.ch8","DOI":"10.1002\/9781119536604.ch8"},{"key":"3713_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JPA, Borm GF (2014) The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol 14:25","journal-title":"BMC Med Res Methodol"},{"key":"3713_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"3713_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22:153\u2013160","journal-title":"Evid Based Ment Health"},{"key":"3713_CR36","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/annonc\/mdz086","volume":"30","author":"NC Turner","year":"2019","unstructured":"Turner NC, Alarc\u00f3n E, Armstrong AC, Philco M, L\u00f3pez Chuken YA, Sablin M-P et al (2019) BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Ann Oncol 30:774\u2013780","journal-title":"Ann Oncol"},{"key":"3713_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10549-021-06143-5","volume":"189","author":"R Dent","year":"2021","unstructured":"Dent R, Oliveira M, Isakoff SJ, Im S-A, Espi\u00e9 M, Blau S et al (2021) Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced\/metastatic triple-negative breast cancer. Breast Cancer Res Treat 189:377\u2013386","journal-title":"Breast Cancer Res Treat"},{"key":"3713_CR38","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.19.00368","volume":"38","author":"P Schmid","year":"2020","unstructured":"Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G et al (2020) Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial. J Clin Oncol 38:423\u2013433","journal-title":"J Clin Oncol"},{"key":"3713_CR39","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1470-2045(22)00284-4","volume":"23","author":"SJ Howell","year":"2022","unstructured":"Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S et al (2022) Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol 23:851\u2013864","journal-title":"Lancet Oncol"},{"key":"3713_CR40","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","volume":"18","author":"S-B Kim","year":"2017","unstructured":"Kim S-B, Dent R, Im S-A, Espi\u00e9 M, Blau S, Tan AR et al (2017) Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 18:1360\u20131372","journal-title":"Lancet Oncol"},{"key":"3713_CR41","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10549-021-06450-x","volume":"191","author":"N Turner","year":"2022","unstructured":"Turner N, Dent RA, O\u2019Shaughnessy J, Kim S-B, Isakoff SJ, Barrios C et al (2022) Ipatasertib plus paclitaxel for PIK3CA\/AKT1\/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res Treat 191:565\u2013576","journal-title":"Breast Cancer Res Treat"},{"key":"3713_CR42","unstructured":"Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis [Internet]. [cited 2024 Jan 23]. Available from: https:\/\/medically.gene.com\/global\/en\/unrestricted\/oncology\/SABCS-2023\/sabcs-2023-presentation-jhaveri-inavolisib-or-placebo-i.html"},{"key":"3713_CR43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1750-9378-8-49","volume":"8","author":"J Bhutani","year":"2013","unstructured":"Bhutani J, Sheikh A, Niazi AK (2013) Akt inhibitors: mechanism of action and implications for anticancer therapeutics. Infect Agent Cancer 8:49","journal-title":"Infect Agent Cancer"},{"key":"3713_CR44","doi-asserted-by":"publisher","first-page":"8778","DOI":"10.1128\/MCB.24.19.8778-8789.2004","volume":"24","author":"S Ugi","year":"2004","unstructured":"Ugi S, Imamura T, Maegawa H, Egawa K, Yoshizaki T, Shi K et al (2004) Protein phosphatase 2A negatively regulates insulin\u2019s metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol 24:8778\u20138789","journal-title":"Mol Cell Biol"},{"key":"3713_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116766","volume":"482","author":"L Chen","year":"2024","unstructured":"Chen L, Qi E, Liu X, Cui L, Fan X, Wei T et al (2024) The lack of homology domain and leucine rich repeat protein phosphatase 2 ameliorates visual impairment in rats with diabetic retinopathy through regulation of the AKT-GSK-3\u03b2-Nrf2 signal cascade. Toxicol Appl Pharmacol 482:116766","journal-title":"Toxicol Appl Pharmacol"},{"key":"3713_CR46","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/bjc.2015.373","volume":"113","author":"E Geuna","year":"2015","unstructured":"Geuna E, Roda D, Rafii S, Jimenez B, Capelan M, Rihawi K et al (2015) Complications of hyperglycaemia with PI3K\u2013AKT\u2013mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. Br J Cancer 113:1541\u20131547","journal-title":"Br J Cancer"},{"key":"3713_CR47","doi-asserted-by":"publisher","first-page":"100776","DOI":"10.1016\/j.currproblcancer.2021.100776","volume":"46","author":"Y-MM Cheung","year":"2022","unstructured":"Cheung Y-MM, McDonnell M, Hamnvik O-PR (2022) A targeted approach to phosphoinositide-3-kinase\/Akt\/mammalian target of rapamycin-induced hyperglycemia. Curr Problems Cancer 46:100776","journal-title":"Curr Problems Cancer"},{"key":"3713_CR48","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","volume":"59","author":"MK Ediriweera","year":"2019","unstructured":"Ediriweera MK, Tennekoon KH, Samarakoon SR (2019) Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance. Semin Cancer Biol 59:147\u2013160","journal-title":"Semin Cancer Biol"},{"key":"3713_CR49","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/cam4.4579","volume":"11","author":"D Liu","year":"2022","unstructured":"Liu D, Weintraub MA, Garcia C, Goncalves MD, Sisk AE, Casas A et al (2022) Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment. Cancer Med 11:1796\u20131804","journal-title":"Cancer Med"},{"key":"3713_CR50","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.annonc.2020.02.007","volume":"31","author":"SJ Isakoff","year":"2020","unstructured":"Isakoff SJ, Tabernero J, Molife LR, Soria J-C, Cervantes A, Vogelzang NJ et al (2020) Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors. Ann Oncol 31:626\u2013633","journal-title":"Ann Oncol"},{"key":"3713_CR51","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH et al (2023) PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 22:138","journal-title":"Mol Cancer"},{"key":"3713_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW et al (2021) Targeting PI3K\/Akt signal transduction for cancer therapy. Sig Transduct Target Ther 6:1\u201317","journal-title":"Sig Transduct Target Ther"},{"key":"3713_CR53","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10549-020-05726-y","volume":"183","author":"DG Wang","year":"2020","unstructured":"Wang DG, Barrios DM, Blinder VS, Bromberg JF, Drullinsky PR, Funt SA et al (2020) Dermatologic adverse events related to the PI3K\u03b1 inhibitor alpelisib (BYL719) in patients with breast cancer. Breast Cancer Res Treat 183:227\u2013237","journal-title":"Breast Cancer Res Treat"},{"key":"3713_CR54","doi-asserted-by":"publisher","first-page":"141","DOI":"10.36401\/JIPO-20-16","volume":"3","author":"PV Karri","year":"2020","unstructured":"Karri PV, Freemyer BD, Pacha O, Patel AB (2020) Characterization of cutaneous adverse events associated with PI3K inhibitors in 11 patients. J Immunother Precis Oncol 3:141\u2013146","journal-title":"J Immunother Precis Oncol"},{"key":"3713_CR55","doi-asserted-by":"publisher","unstructured":"(2021) AKT question relating to child with a rash. InnovAiT 14:e56\u2013e56. https:\/\/doi.org\/10.1177\/17557380211005669c","DOI":"10.1177\/17557380211005669c"},{"key":"3713_CR56","doi-asserted-by":"publisher","unstructured":"(2020) AKT answer relating to skin rash [Internet]. [cited 2024 Jan 23]. https:\/\/doi.org\/10.1177\/1755738020940215g","DOI":"10.1177\/1755738020940215g"},{"key":"3713_CR57","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3390\/antiox11091845","volume":"11","author":"J-P Shiau","year":"2022","unstructured":"Shiau J-P, Chuang Y-T, Tang J-Y, Yang K-H, Chang F-R, Hou M-F et al (2022) The impact of oxidative stress and AKT pathway on cancer cell functions and its application to natural products. Antioxidants (Basel) 11:1845","journal-title":"Antioxidants (Basel)"},{"key":"3713_CR58","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1038\/jcbfm.2008.80","volume":"28","author":"YS Song","year":"2008","unstructured":"Song YS, Narasimhan P, Kim GS, Jung JE, Park E-H, Chan PH (2008) The role of Akt signaling in oxidative stress mediates NF-\u03baB activation in mild transient focal cerebral ischemia. J Cereb Blood Flow Metab 28:1917\u20131926","journal-title":"J Cereb Blood Flow Metab"},{"key":"3713_CR59","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.oraloncology.2011.08.009","volume":"47","author":"MA de Oliveira","year":"2011","unstructured":"de Oliveira MA, Martins e Martins F, Wang Q, Sonis S, Demetri G, George S et al (2011) Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol 47:998\u20131003","journal-title":"Oral Oncol"},{"key":"3713_CR60","doi-asserted-by":"publisher","first-page":"107327482311683","DOI":"10.1177\/10732748231168318","volume":"30","author":"Z Heidary","year":"2023","unstructured":"Heidary Z, Ghaemi M, Hossein Rashidi B, Kohandel Gargari O, Montazeri A (2023) Quality of life in breast cancer patients: a systematic review of the qualitative studies. Cancer Control 30:10732748231168318","journal-title":"Cancer Control"},{"key":"3713_CR61","doi-asserted-by":"publisher","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","volume":"30","author":"SE Nunnery","year":"2019","unstructured":"Nunnery SE, Mayer IA (2019) Management of toxicity to isoform \u03b1-specific PI3K inhibitors. Ann Oncol 30:x21\u2013x26","journal-title":"Ann Oncol"},{"key":"3713_CR62","doi-asserted-by":"publisher","first-page":"x12","DOI":"10.1093\/annonc\/mdz381","volume":"30","author":"B Verret","year":"2019","unstructured":"Verret B, Cortes J, Bachelot T, Andre F, Arnedos M (2019) Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol 30:x12-20","journal-title":"Ann Oncol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03713-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03713-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03713-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T08:15:07Z","timestamp":1722932107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03713-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":62,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["3713"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03713-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"22 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}